The inclusion of tildrakizumab injection in NRDL will further boost Sun Pharma commercialisation efforts globally. NRDL is a list of drugs fully or partially reimbursed by the national basic health insurance in China covering 96% of the population or more than 1.36 billion people.
Two posters presented at the 2023 Fall Clinical Dermatology Conference assessed phase 4 study findings on tildrakizumab in patients with moderate to severe plaque psoriasis.
In these preliminary results from the ongoing POSITIVE study, tildrakizumab was shown to have led to significant improvement for patients who have psoriasis.
Strict inclusion and exclusion criteria in clinical trials means findings on health-related quality of life (HRQOL) may not be generalizable to the real-world setting.
ITALY: Tildrakizumab was found to be beneficial for up to 36 weeks in treating moderate-to-severe plaque psoriasis, according to a new study published in the Journal of the European Academy of.